Avid Bioservices Inc (CDMO)

[honestabe13]

U.S. and European officials may decide this week that Roche's top drug should no longer be approved for breast cancer, an unusual step that could shave $1 billion from annual sales as insurers refuse coverage.

Avastin is the world's best-selling cancer medicine and one of the most expensive, a fact that fuels controversy.

It carries approval for fighting breast and other cancers, but the drug has not extended survival or improved symptoms in any study of patients with breast cancer.